|
業務類別
|
Biotechnology |
|
業務概覽
|
Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. |
| 公司地址
| 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07922 |
| 電話號碼
| +1 862 799-8599 |
| 傳真號碼
| +1 212 923-5700 |
| 公司網頁
| https://www.tonixpharma.com |
| 員工數量
| 81 |
| Dr. Seth Lederman, M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 702.00K |
30/03/2026 |
| Dr. Gregory M. Sullivan, M.D. |
Chief Medical Officer and Secretary |
美元 519.17K |
12/03/2026 |
| Ms. Jessica Edgar Morris |
Chief Operating Officer |
美元 522.91K |
12/03/2026 |
| Mr. Bradley Saenger, C.P.A. |
Chief Financial Officer, Principal Accounting Officer and Treasurer |
美元 502.94K |
12/03/2026 |
| Ms. Siobhan Fogarty |
Chief Technology Officer |
-- |
12/03/2026 |
|
|
| Dr. Adeoye Y. Olukotun, M.D. |
Independent Director |
30/03/2026 |
| General David L. Grange |
Independent Director |
30/03/2026 |
| Mr. Richard H. Bagger |
Independent Director |
30/03/2026 |
| Dr. Seth Lederman, M.D. |
Chairman of the Board, President and Chief Executive Officer |
30/03/2026 |
| Ms. Margaret Smith Bell |
Independent Director |
30/03/2026 |
| Mr. James Randolph Hunter, Jr |
Director |
30/03/2026 |
| Mr. James Treco |
Lead Independent Director |
30/03/2026 |
| Mr. Richard Newcomb Stillwell |
Independent Director |
30/03/2026 |
| Ms. Carolyn E. Taylor |
Independent Director |
30/03/2026 |
|
|
|
|
